Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion’s Tracleer Hangs On Against Label-Dampened Letairis

This article was originally published in The Pink Sheet Daily

Executive Summary

Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.

You may also be interested in...



Risk Management Plans Are In Fact A “Big Deal,” FDA Tells Gilead

FDA's citation of Gilead for downplaying the risk management plan for its pulmonary arterial hypertension product Letairis (ambrisentan) is noteworthy for what it doesn't cite as much for what it does

Risk Management Plans Are In Fact A “Big Deal,” FDA Tells Gilead

FDA's citation of Gilead for downplaying the risk management plan for its pulmonary arterial hypertension product Letairis (ambrisentan) is noteworthy for what it doesn't cite as much for what it does

Oral Remodulin's Early PK Data Look Good

Pill makes gradual hiking of dosage easier.

Related Content

Topics

UsernamePublicRestriction

Register

PS067291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel